Highlights include: • Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. • MGUS risk in relatives of patients with multiple myeloma. • Costs of peripheral neuropathy in patients treated for multiple myeloma. Download here: Multiple Myeloma Research Review Issue 30Continue Reading